Skip to main content

The independent medical news service

Lung cancer

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

31-01-2019 | Lung cancer | News | Article

Lung cancer OS benefit with patient-reported symptom monitoring

A web-based patient-reported system for monitoring symptoms after treatment for lung cancer is associated with significantly better overall survival than standard scheduled imaging, trial results show.

30-01-2019 | Non-small-cell lung cancer | News | Article

MET copy number gain insignificant for TKI response in EGFR-positive NSCLC

The level of mesenchymal epithelial transition factor copy number gain does not affect response to tyrosine kinase inhibitors in patients with metastatic epidermal growth factor receptor-mutated non-small-cell lung cancer, research shows.

18-01-2019 | Non-small-cell lung cancer | News | Article

Prolonged OS possible for ALK-positive stage IV NSCLC

Individuals with stage IV non-small-cell lung cancer harboring anaplastic lymphoma kinase translocations can hope to achieve overall survival of nearly 7 years, suggests a US cohort analysis.

15-01-2019 | Non-small-cell lung cancer | News | Article

miRNA signature could supplement PD-L1 as NSCLC immunotherapy marker

Combining a plasma-based microRNA signature with tumoral tissue expression of programmed cell death ligand 1 could help identify advanced non-small-cell lung cancer patients who are unlikely to benefit from immune checkpoint inhibition, suggests an exploratory study.

11-01-2019 | Oncology | News | Article

Concomitant TKI–PPI use may adversely affect cancer patient survival

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

10-01-2019 | Non-small-cell lung cancer | News | Article

Autoimmune antibodies predict clinical benefit, adverse events in NSCLC

The presence of some autoimmune antibodies prior to treatment with programmed cell death protein 1 inhibitors is associated with both clinical benefit and immune-related adverse events in patients with non-small-cell lung cancer, researchers report.

04-01-2019 | Oncology | News | Article

Atezolizumab, larotrectinib approvals announced by FDA

More information on use of these agents here

21-12-2018 | Lung cancer | News | Article

Lung cancer ctDNA sequencing allows timely initiation of targeted therapy

Digital next-generation sequencing of circulating tumor DNA is a clinically useful option for advanced lung adenocarcinoma patients with insufficient tumor biopsy samples, say researchers.

21-12-2018 | Non-small-cell lung cancer | News | Article

Clinical course of EGFR-mutant NSCLC transforming to SCLC documented

Epidermal growth factor receptor-mutant non-small-cell lung cancer that transforms to small-cell lung cancer is characterized by a high rate of TP53 mutation and a lack of response to immunotherapy, among other features, show researchers.

14-12-2018 | Small-cell lung cancer | News | Article

Veliparib shows efficacy in some patients with extensive-stage SCLC

Some patients with extensive-stage small-cell lung cancer may benefit from the addition of the poly(ADP ribose) polymerase inhibitor veliparib to standard chemotherapy, but further confirmation of its efficacy is needed, say researchers.

03-12-2018 | Oncology | News | Article

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

26-11-2018 | Oncology | News | Article

Adjuvant erlotinib delays recurrence in stage IA–IIIA NSCLC

Adjuvant erlotinib significantly prolongs disease-free survival, compared with a historic benchmark, in patients with epidermal growth factor receptor-mutated stage IA–IIIA non-small-cell lung cancer, US research shows.

19-11-2018 | Oncology | News | Article

Clinically important safety differences found among immune checkpoint inhibitors

A network meta-analysis has ranked the safety of immune checkpoint inhibitors in cancer treatment, with atezolizumab revealed to have the best general safety profile.

13-11-2018 | Lung cancer | Main feed | News

Lorlatinib shows promising activity against ALK-positive advanced NSCLC

Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.

05-11-2018 | Lung cancer | Main feed | News

Impact of undertreatment on reduced survival in older lung cancer patients quantified

A modeling study presented at the 2018 NCRI Conference in Glasgow, UK, estimates that around 38% of the survival difference between older and younger patients with lung cancer may be due undertreatment in the older age group.

01-11-2018 | Non-small-cell lung cancer | News | Article

Neoadjuvant erlotinib evaluated for EGFR-mutated stage IIIA-N2 NSCLC

The CTONG-1103 EMERGING trial investigators believe that neoadjuvant treatment with epidermal growth factor receptor–tyrosine kinase inhibitors for stage IIIA-N2 non-small-cell lung cancer warrants further investigation.

31-10-2018 | Oncology | News | Article

ALESIA confirms first-line alectinib benefit in Asian advanced NSCLC patients

The ALESIA trial comprising treatment-naïve patients with advanced anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer confirms the systemic and intracranial efficacy of alectinib over crizotinib in an Asian population.

19-10-2018 | Non-small-cell lung cancer | News | Article

Dual MET–EGFR inhibition promising for relapsed MET-high NSCLC

Combining the highly selective MET inhibitor tepotinib with gefitinib could benefit patients with non-small-cell lung cancer that has progressed on first-line treatment with an EGFR–tyrosine kinase inhibitor and has high levels of MET, suggest phase II trial results.

19-10-2018 | Lung cancer | News | Article

Adding plasma NGS testing to routine NSCLC management could aid targeted therapy delivery

Plasma-based next-generation sequencing may help to identify therapeutically targetable mutations in patients with metastatic non-small-cell lung cancer, suggests research published in JAMA Oncology.

image credits